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Since the approval of the first stent by the US Food and Drug
Administration, stents have been developed from bare metal
stents to advanced forms such as drug-eluting stent (DES).
However, after being inserted into damaged coronary arter-
ies, even modern DES still has some problems such as late
thrombosis or irregular drug release [1,2].
For the effective prevention of these problems, in this
study, we fabricated the dual functional stent that has two
differently coated surfaces, outer (abluminal) and inner (luminal)
sides, as a novel type of DES. Sirolimus (SRL) and dopamine-
conjugated hyaluronic acid (HA-DA) were coated on abluminal
and luminal sides of a bare cobalt-chromium (Co-Cr) alloy
stent, respectively. X-ray photoelectron spectroscopy, water
contact angle measurement, attenuated total reflection-
Fourier transform infrared spectroscopy, atomic force
microscopy, and field-emission scanning electron micros-
copy were performed to characterize each coating. Moreover,
we assessed the in vitro drug release patterns using some
diverse additives and solvents. According to our results,
Co-Cr alloy stents with SRL and HA-DA (SRL/HA stent) were
successfully coated on abluminal and luminal sides, respec-
tively. The SRL/HA stent showed more sustained pattern of
drug release than only polymer/SRL (PS) coated stents. In
addition, the SRL/HA stent had less crack on polymer sur-
faces after ballooning as compared to PS stent. The results
suggest that HA-DA can be used as an additional factor to
adjust the drug release pattern and, SRL/HA stent has not
only an adequate drug release pattern within desired period
at time but also a more flexible effect on preventing the
cracking formation. It is expected that this type of DES can
be employed to treat the complex lesions by utilizing diverse
drugs and biopolymers (Fig. 1).
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Fig. 1 – SEM images (A), ATR-FTIR spectra (B), and in vitro release profiles of SRL (C).
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